Increased volume of distribution for recombinant activated factor VII and longer plasma-derived factor VII half-life may explain their long lasting prophylactic effect  by Mathijssen, Natascha C.J. et al.
Thrombosis Research 132 (2013) 256–262
Contents lists available at ScienceDirect
Thrombosis Research
j ourna l homepage: www.e lsev ie r .com/ locate / thromresRegular Article
Increased volume of distribution for recombinant activated factor
VII and longer plasma-derived factor VII half-life may explain their
long lasting prophylactic effect
Natascha C.J. Mathijssen a, Rosalinde Masereeuw b, Pal Andre Holme c, Marian G.J. van Kraaij d,
Britta A.P. Laros-van Gorkom e, Flora Peyvandi f, Waander L. van Heerde a,⁎
a Laboratory of Haematology, Department of Laboratory Medicine, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
b Department of Pharmacology and Toxicology, Radboud University Nijmegen Medical Centre/Nijmegen Centre for Molecular Life Sciences, Nijmegen, The Netherlands
c Department of Haematology, Oslo University Hospital, Rikshospitalet, Oslo, Norway
d Department of Transfusion Consultancy, Sanquin Blood Bank South East, Nijmegen, The Netherlands
e Department of Haematology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
f
Plasma-derived factor VII
Abbreviations: pdFVII, Plasma-derived factor VII; rFV
tor VII; FVII, Factor VII; NCA, Non-Compartmental Analy
Analysis; Hb, Hemoglobin; T½, Half-life; Cmax, Peak p
after administration; IVR, Incremental In Vivo Recove
MRT, Mean Residence Time; AUC, Area Under the Curv
at steady-state.
⁎ Corresponding author at: Laboratory of Hematolo
Medicine, P.O. box 9101, 6500 HB Nijmegen, The Nethe
fax: +31 243568408.
E-mail address: w.vanheerde@labgk.umcn.nl (W.L. v
0049-3848/$ – see front matter © 2013 Elsevier Ltd. All
http://dx.doi.org/10.1016/j.thromres.2013.05.027ntre, IRCCS Maggiore Hospital Foundation and University of Milan, Milan, Italy
a b s t r a c tAngelo Bianchi Bonomi Haemophilia and Thrombosis Cea r t i c l e i n f oArticle history: Introduction: Prophylaxis with plasma-derived or recombinant activated factor VII is beneﬁcial in severe fac-
Received 26 November 2012 tor VII deﬁciency. To understand why prophylactic treatment with both products is efﬁcacious, we conducted
Received in revised form 25 April 2013 a pharmacokinetic study.
Accepted 27 May 2013 Materials and Methods: Ten factor VII deﬁcient patients were treated with either recombinant activated
Available online 6 July 2013 (20 μg/kg) or plasma-derived (25 IU/kg) factor VII in a cross-over design. Pharmacokinetic parameters
were analyzed through activated factor VII activity, factor VII clotting activity, and factor VII antigen levels
Keywords:
on depicted time points.Hemostasis
Results:Factor VII Factor VII activity half-lifes, determined by non-compartmental and one-compartmental analysis
Coagulation (results in brackets), were shorter for recombinant activated (1.4 h; 0.7 h) than for plasma-derived factor
Pharmacokinetics VII (6.8 h; 3.2 h); both recombinant activated (5.1 h; 2.1 h and plasma-derived factor VII (5.8 h; 3.2 h)
Recombinant activated factor VII resulted in longer half-lives of factor VII antigen. Activated factor VII half-lives (based on activated factorVII activity levels) were signiﬁcantly higher compared to factor VII clotting activity (1.6 h; 0.9 h). Volumes
of distribution were signiﬁcantly higher for activated factor VII (236 ml/kg; 175 ml/kg, measured by activat-
ed factor VII) as compared to plasma-derived factor VII (206 ml/kg; 64 ml/kg, measured by factor FVII activ-
ity), suggesting a plasma- and extracellular ﬂuid distribution for recombinant activated factor VII.
Conclusions: Recombinant activated factor VII showed signiﬁcantly shorter half-lifes than plasma-derived fac-
tor VII. Volumes of distribution were signiﬁcantly higher for treatment with recombinant activated factor VII.
The longer half-life for plasma-derived factor VII, compared to recombinant activated factor VII, and the in-
creased volume of distribution for recombinant activated factor VII, compared to plasma-derived factor VII
may further elucidate the beneﬁcial effect of prophylactic treatment of both products.© 2013 Elsevier Ltd. All rights reserved.Introduction
Inherited factor VII (FVII) deﬁciency is a rare autosomal recessive
disorder, associated with a bleeding tendency. Bleeding episodes in
FVII deﬁcient patients are treated with either plasma-derived factorIIa, Recombinant activated fac-
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rights reserved.VII (pdFVII) or recombinant activated factor VII (rFVIIa). Both are
also used for prophylactic treatment [1–4] despite reported half-lifes
of 3–5 hours and 2–3 hours for pdFVII and rFVIIa, respectively [5–8].
Since FVII deﬁciency is so rare, most reports on the pharmacokinetic
properties of these products concern only small numbers of patients,
if not single case reports [3,4,6–10]. So far no study reported a compar-
ison of pdFVII versus rFVIIa pharmacokinetics within a group of pa-
tients with FVII deﬁciency.
Since rFVIIa treatment is more widely applied than pdFVII [11], the
pharmacokinetics of rFVIIa has already been determined in healthy
volunteers and patients with other bleeding problems, e.g. haemophilia
A [1,5,12]. Klitgaard et al. provided an overview of reports describing
rFVIIa pharmacokinetics in healthy volunteers, in patients with hemo-
philia A with inhibitory antibodies, FVII deﬁcient patients and several
other patient groups [13]. Notably, several pharmacokinetic analysis
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and one compartmental analysis (OCA). Both methods have their
(theoretical) advantages. OCA uses a method of maximum likelihood
and ﬁts a curve reﬂecting the concentration-time data over the entire
time-span. OCA is model-dependent since it assumes that the admin-
istered product is distributed over one compartment only or that
distribution in other compartments is limited. NCA requires fewer
assumptions and is often applied to cases with limited concentration-
time data points [14]. However, NCA can not take time-varying condi-
tions into account, such as changes in hemodynamics, and pharma-
cokinetic parameters estimated under such conditions are often less
reliable.
In this report, we present results of a cross-over study in FVII deﬁ-
cient patientswith FVII activity levels less than 2%who are given a sin-
gle dose of either rFVIIa and pdFVII followed by pharmacokinetic
analysis.We hypothesized that robust analysis of pharmacokinetic pa-
rameters will improve our understanding on why prophylaxis with
both products is reported to be efﬁcacious in patients with severe fac-
tor VII deﬁciency. The pharmacokinetic parameters of a single dose of
rFVIIa or pdFVII were analyzed by NCA as well as OCA in order to de-
termine which method is most reliable for each product.
Materials and Methods
Patients
The study adhered to the Declaration of Helsinki andwas approved
by the local ethics committees in Nijmegen, Norway and Milan and
registered at the ISRCTN register (ISRCTN04929580). Ten FVII deﬁ-
cient patients were included and randomized by permuted block
randomization into two groups of ﬁve individuals. Inclusion was
based on FVII activity levels of less than 5%, age older than 18 years,
a run-in periodwithout studymedication of at least three days and in-
tention to participate. Exclusion criteria were known allergy to plasma
proteins, a bleeding episode causing a drop in hemoglobin (Hb) levels
of >1 mmol/l, trauma or surgery during the last six weeks, fever
(>38 °C), clinical indication of liver cirrhosis (echographic indication,
enlarged spleen, enlarged liver, decreased platelet count), hepatitis C
infection recently treated with interferon (six month wash-out peri-
od), HIV-positivity, pregnancy, use of NSAIDs, clopidogrel, antimicro-
bial medication, thyroid inhibitors or SSRI’s, Hb levels b7.5 mmol/l
for women and b8.4 mmol/l for men.
Patients were treated with either intravenous rFVIIa (Novo Nordisk
AS, Denmark, 20 μg/kg) followed –after an interval of at least six
weeks- by intravenous administration of pdFVII (Baxter, Vienna, Austria,
25 IU/kg) or vice versa. The administered doses of rFVIIa and pdFVIITable 1
Patient characteristics. Patient numbers reﬂect the order of their participation in the study
Patient Age
(yr)
Sex Weight
(kg)
Country FVII act
(%)
FVII ag
(%)
1 39 M 113 Netherlands b2 20
2 43 M 82 Norway b2 11
3 45 F 55 Norway b2 17
4 43 F 60 Norway b2 14
5 48 F 47 Italy b2 3
6 21 F 63 Netherlands b2 14
7 18 M 76 Netherlands b2 6
8 34 F 60 Netherlands b2 2
9 19 M 60 Netherlands b2 40
10 18 M 58 Norway b2 12
Median 37 60 b2 13were similar to those used for prophylaxis. Although the dosages for
both products are not pharmacologically comparable, it was decided to
adhere to the clinically used dosages.
Blood sampling occurred before administration of rFVIIa or pdFVII
(exact dose see Table 1) and 5, 10, 15, 30 min and 1, 2, 3, 4, 6, 24, and
48 h after administration. In between the two visits the patients ad-
hered to their normal treatment for FVII deﬁciency with another
run-in period of 3 days without administering factor VII containing
drugs before the second visit.
FVII Antigen, FVII Activity and FVIIa Activity Levels
FVIIa activity, FVII activity levels as well as FVII antigen levels
were determined in CTAD plasma (citrate/theophylline/adenosine/
dipyridamole). FVIIa activity was determined using a one-stage clotting
assay (STACLOT® VIIa-rTF, Diagnostica Stago, Asnières sur Seine,
France) containing human recombinant soluble tissue factor (rsTF).
This rsTF does not activate FVII zymogen by auto-activation and, there-
by, ensures measuring of exclusively FVIIa activity [15]. FVII activity
levels were measured with a chromogenic assay (Biophen FVII, Nodia,
Amsterdam, The Netherlands). FVII antigen levels were measured
using standard ELISA (Zymutest FVII, Nodia, Amsterdam, The Nether-
lands). One IU FVII antigen or FVII activity corresponds to 500 ng FVII,
one IU FVIIa activity concurs with 20 ng FVIIa. All measurements were
performed according to the manufacturer’s instructions accompanying
the kits.
Maximum levels of FVIIa activity, FVII activity levels and FVII anti-
gen after administration, as well as time to maximum concentration,
time to 10% FVII activity and time to minimum (lowest concentra-
tions) were determined using results of all three FVII assays.
Determination of FVIIa Inhibitory Activity
A mixing test based on the FVIIa activity assay was used to deter-
mine the presence of FVIIa inhibitory activity, similar to the Oxford
method for the determination of FVIII inhibitors [16]. A ﬁxed dose of
rFVIIa was added to either control plasma (FVII deﬁcient plasma) or
untreated patient plasma. Immediately after adding rFVIIa, the FVIIa ac-
tivity was measured as described above with the minor modiﬁcation
that the incubation time was shortened to 30 seconds. Incubation
times were kept so short to prevent premature degradation of rFVIIa
(personal observations). The presence of FVII inhibitory activity was
suggested when the patient sample showed lower FVIIa activity than
the control sample. To conﬁrm that the activity was IgG related, total
IgG was removed from patient plasma by applying the plasma to a
protein-G column, before performing the same mixing test. Similar(M: male, F: female).
Standard treatment
product
Prophylaxis or
On demand
rFVIIa dose in
study (μg/kg)
pdFVII dose in
study (IU/kg)
rFVIIa On demand 21.2 26.5
Since 2002 rFVIIa
Previously pdFVIIa
On demand 19.5 29.2
Since 2004 rFVIIa
Previously pdFVII
On demand 21.8 27.3
rFVIIa On demand 20.0 30.0
pdFVIIa Prophylaxis
2*600 U/week
21.3 25.5
rFVIIa Prophylaxis
2*1.2 mg/week
19.0 28.6
pdFVII Prophylaxis
2*1200 U/week
19.7 23.7
pdFVII On demand 20.0 30.0
pdFVII On demand 16.7 30.0
rFVIIa
previously pdFVII
On demand 20.7 25.9
20 28
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FVIIa inhibitory activity was IgG related.
Pharmacokinetic Analysis
Pharmacokinetics were assessed according to NCA and OCAwith in-
travenous bolus administration and ﬁrst-order elimination by using the
nonlinear least square regression program software,WinNonlin version
5.2 (Pharsight Corp., Mountain View, CA, USA). To assess pharmacoki-
netics for both rFVIIa and pdFVII, the FVIIa and FVII activities and FVII
antigen levels were determined.
One-compartmental Analysis (OCA)
This model considers the body as a single homogeneous compart-
ment, assuming single rate elimination of the entire dose of rFVIIa or
pdFVII. In this model, a graph is ﬁtted to the actual measured FVII(a)
levels and from that the different pharmacokinetic parameters are cal-
culated. This way all time-points from the entire experiment are taken
into account.
Individual plasma FVIIa and FVII levels versus time data were an-
alyzed assuming an intravenous bolus infusion and a ﬁrst order elim-
ination rate. Pharmacokinetic parameters determined from each
curve were the half-life (t1/2), total body clearance (Cl), peak plasma
concentration of a drug after administration (Cmax), mean residence
time (MRT), area under the curve (AUC), and volume of distribution
at steady-state (Vss). Goodness-of-ﬁt was evaluated as the deviation
between observed and model-predicted values, by means of the Re-
sidual Sums of Squares, correlation coefﬁcients and observed versus
predicted plots. Incremental In Vivo Recovery (IVR) was calculated
as a ratio between Cmax and dose/kg. All analyses were corrected
for residual FVIIa or FVII levels.
Noncompartmental Analysis (NCA)
With NCA no assumptions are made concerning the number of
compartments the drug is taken into [14]. For NCA, an IV-bolus dosing
model was used to assess concentration data. Same parameters as de-
scribed for OCA were determined, using the rate constant λz, associ-
ated with the terminal elimination phase for concentration data.
Goodness of ﬁt (R2) was evaluated for the terminal elimination
phase, adjusted for the number of points used in the estimation of
λz. All analyses were corrected for residual FVIIa or Factor VII levels.
Statistical Analysis
Statistical differences between analyses were determined with the
Wilcoxon Signed Ranks test for comparison of paired data sets. All
statistical analyses were performed using GraphPad Prism (GraphPad
Software, La Jolla, CA, USA).
Results
Patient Characteristics
Five male and ﬁve female patients were included into the study.
They originated from Italy (n = 1), The Netherlands (n = 5) and
Norway (n = 4). All patients participated into this study in Nijmegen
(The Netherlands) except for one patient (no. 5) who participated in
Milan. The median age was 37 years (range 18–48). Bodyweight
ranged from 47 to 113 kg (median 60 kg). Before administration of
rFVIIa or pdFVII, all patients had FVII activity levels of less than 2%.Me-
dian FVII antigen levels were 13 % (range 2-40%). All patients had sig-
niﬁcant bleeding histories. Patient characteristics are summarized in
Table 1 including the given doses of rFVIIa and pdFVII. No adverse
events occurred in any of the patients during their participation in
this study, except for one patient who gained a FVIIa inhibitor during
the study as is described below.Patient with FVIIa Inhibitory Activity
During the second visit of patient 4 upon rFVIIa administration, less
then 10% recovery (18 ng/ml) was measured which was much lower
as compared to the medianmaximum levels of other patients after in-
jection with rFVIIa (250 ng/ml; range 84–345 ng/ml). When rFVIIa
was injected during visit two, patient 4 experienced a non-severe
allergic reaction at the injection site (itching and urticaria), which re-
solved spontaneously. The sample taken from this patient at the start
of visit two tested positive for FVIIa inhibitory activity. The FVIIa inhib-
itory activity was due to a FVII immunoglobulin G antibody as the
inhibitory activity could be eliminated from the patients’ plasma
with a protein G-column. The development of inhibitory antibodies,
although relatively common in patients with severe hemophilia A, is
quite rare in patients with FVII deﬁciency [2]. In this case, the causality
of this event could not be determined; the patient was treated with
rFVIIa before without clinical evidence for inhibitory activity, and no
inhibitory activity was present in the samples from visit one. In addi-
tion, the patient used rFVIIa during the time between the two study
visits.
Approximately one year after the end of the study period, patient
4 had surgery under rFVIIa prophylaxis with normal rFVIIa yields and
without complications. Because of the presence of an inhibitory anti-
body during the study period, all data of this patient were excluded
from further analyses. None of the other patients displayed FVIIa in-
hibitory activity neither clinically nor measured in plasma.
FVIIa Activity, FVII Activity and FVII Antigen Levels
Administration of rFVIIa
After rFVIIa administration, the FVIIa and FVII activities and FVII
antigen rose to amaximumwithin 5 minutes (Table 2, Fig. 1). Theme-
dian FVIIa levels were signiﬁcantly higher when compared to the me-
dian levels of FVII activity and antigen levels. During the next 24 hours
FVIIa activity decreased to baseline (Table 2, Fig. 1A). Amore rapid de-
crease was observed for FVII activity (Table 2, Fig. 1B). However, both
FVIIa activity and FVII activity reached a 10% levels at 2 hrs. Factor VII
antigen levels showed a gradual decrease in levels within approxi-
mately 48 hours (Table 2, Fig. 1C).
Administration of pdFVII
Plasma-derived FVII also caused increased activity of both FVIIa,
FVII, and FVII antigen. As expected, the maximum FVIIa activity levels
were much lower than the levels reached after rFVIIa injection
(Table 2, Fig. 1A). The maximum FVII activity levels were reached
slightly later and were somewhat lower after pdFVII administration
when compared to rFVIIa, but FVII levels remained elevated for a
longer period of time (Table 2, Fig. 1B). The difference on FVIIa and
FVII activity levels observed after administration of either rFVIIa or
pdFVII was not seen for FVII antigen levels although on average slight-
ly lower FVII antigen levels were measured upon pdFVII administra-
tion (Table 2, Fig. 1C).
Pharmacokinetic Analysis of FVIIa Activity and FVII Antigen Levels after
rFVIIa and pdFVII Administration
The NCA and OCA pharmacokinetic data of rVIIa and pdFVII are
shown in Table 3 and Fig. 2. In general, individual and median Vss,
AUC, Cmax, IVR, MRT and half-life values for both products were
signiﬁcantly higher when calculated by NCA, compared to OCA. The
higher Vss, AUC and half-life values estimated by NCA, corresponded
with lower Cl levels. We did not report the PK results of pdFVII based
on FVIIa activity levels as the levels of FVIIa activity are near the de-
tection limit of the assay. Moreover, all data based on FVIIa levels in
pdFVII treated patients were not analyzed.
Table 2
Maximum levels, time to maximum, time to FVII b 10% and time to minimum levels for individual patients. Patient 4 was excluded for the calculation of median levels and 25-75%
interquartile ranges.
Patient Treatment Maximum levels expressed in ng/mL (between brackets in
IU/dL))
Time to maximum (min) Time to FVII b10% (h) Time to minimum (h)
FVIIa Act FVII Act FVII Ag FVIIa
Act
FVII
Act
FVII
Ag
FVIIa
Act
FVII
Act
FVII
Ag
FVIIa
Act
FVII
Act
FVII
Ag
1 rFVIIa 314 (1570) 320 (64) 705 (141) 15 10 5 3 2 >48 24 3 48
pdFVII 2.7 (13.5) 95 (19) 425 (85) 60 5 10 24 2 >48 24 6 48
2 rFVIIa 166 (830) 270 (54) 385 (77) 5 5 5 3 2 >48 24 3 24
pdFVII 7.7 (38.5) 95 (19) 355 (71) 30 10 5 24 3 >48 24 6 24
3 rFVIIa 261 (1305) 385 (77) 340 (68) 5 10 5 3 3 >48 24 3 48
pdFVII 1.7 (8.5) 50 (10) 255 (51) 5 10 5 48 1 >48 24 24 24
4 rFVIIa 18 (90) b25 (b5) 220 (44) 10 n.a. 5 n.a. n.a. >48 24 n.a. 4
pdFVII 4.0 (20) 365 (73) 325 (65) 60 30 5 6 6 >48 6 6 6
5 rFVIIa 154 (770) 120 (24) 235 (47) 5 5 5 2 0.5 24 48 1 24
pdFVII 2.0 (10) 150 (30) 220 (44) 5 15 5 24 4 >48 24 24 24
6 rFVIIa 250 (1250) 755 (151) 330 (66) 5 5 5 1 1 >48 24 3 24
pdFVII 1.0 (5.0) 225 (45) 335 (67) 10 5 5 6 3 >48 24 6 24
7 rFVIIa 345 (1725) 1450 (290) 485 (97) 5 5 5 2 2 >48 24 6 24
pdFVII 3.7 (18.5) 270 (54) 230 (46) 5 15 10 24 3 >48 24 24 24
8 rFVIIa 255 (1275) 620 (124) 285 (57) 5 10 5 2 2 24 24 4 48
pdFVII 4.0 (20) 200 (40) 285 (57) 5 5 10 24 6 >48 24 24 48
9 rFVIIa 143 (715) 455 (91) 405 (81) 5 10 30 3 3 >48 24 6 48
pdFVII 4.3 (21.5) 205 (41) 365 (73) 5 5 5 24 6 >48 24 24 48
10 rFVIIa 84 (420) 345 (69) 255 (51) 10 5 10 2 2 >48 24 3 48
pdFVII 0.7 (3.5) 225 (45) 260 (52) 5 10 30 24 6 >48 24 24 48
rFVIIa Median 250 (1250) 385 (77) 340 (68) 5 5 5 2 2 >48 24 3 48
25-75 IQR 149-288 (745-1440) 295-690 (59-138) 270-445 (54-89) (5-7.5) (5-10) (5-7.5) (2-3) (1.5-2.5) (24->48) (24-24) (3-5) (24-48)
pdFVII Median 2.7 (13.5) 200 (40) 285 (57) 5 5 5 24 4 >48 24 24 24
25-75 IQR 1.4-4.2 (7.0-21) 95-225 (19-45) 245-360 (49-72) (5-7) (5-13) (5-10) (24-24) (3-6) (>48->48) (24-24) (6-24) (24-48)
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showed signiﬁcantly shorter half-lives of rFVIIa when compared to
the half-lives of pdFVII based on calculations of FVII activity and FVII
antigen levels (only exception NCA calculations with FVII ag levels,
p = 0.46). A similar pattern was observed for AUC, Cl and MRT. For
Vss only a trend to higher Vss levels were observed for rFVIIa on
basis of FVII and FVII antigen levels. However, a direct comparison of
the Vss levels of rFVIIa based on FVIIa activity levels as compared to
the Vss levels of pdFVII as measured with FVII levels showed a signif-
icantly higher Vss level for rFVIIa. Finally, the pharmacokinetic results
after administration of rFVIIa differed signiﬁcantly if determined with
FVIIa activity when compared to the pharmacokinetic results if deter-
mined with FVII activity and FVII antigen. All statistical analyses are
summarized in Table 1 of the Supplementary material.
Finally a direct comparison of the IVR between rFVIIa and pdFVII
showed signiﬁcantly lower levels for determination based on factor
VII activity levels (OCA, p b 0.05; NCA, p b 0.01). Based on FVII antigen
levels IVR levels were comparable for both mathematical approaches
(p > 0.05).
Discussion
We performed a pharmacokinetic cross-over study in ten patients
with factor VII deﬁciency to determine the pharmacokinetic proper-
ties of rFVIIa and pdFVII based on FVIIa activity, FVII activity and
FVII antigen levels. The rationale for this study was that prophylactic
treatment of these patients (with two to three injections per week)
showed beneﬁcial effects in several case reports despite the short
half-lifes of both products and that some patients showed a clinical
preference for one product over the other.
Our pharmacokinetic determinations are based on 12 time points
spanning a timeframe of 48 hours. The FVIII/IX SSC committee of the
ISTH recommends sampling for maximally 8 hours. Our results sup-
port this recommendation but only if sufﬁcient time points are in-
cluded within one hour; e.g. minimally 15 en 30 minutes.
The design of this study, with a large number of blood samples on
the ﬁrst day and only two sampling points in the terminal phase (24 hand 48 h), provides certain beneﬁts for the OCA model over the NCA
model, since the latter is often used in studies with limited samples.
Less inter-individual variation was observed with OCA, probably
because NCA relies heavily on the last data points, which are almost
always near or even under the limits of FVII activity assays. However,
OCA is based on the assumption that rFVIIa of pdFVII are only present
in blood or that the kinetics in other ﬂuids and tissues do not differ
from those in blood. We observed increased volumes of distribu-
tion of rFVIIa with ﬁts with the described extravascular localization
of rFVIIa space [17] indicating that rFVIIa is not restricted to one com-
partment, but analyzing data according to a two-compartment model
did not resulted in signiﬁcantly better ﬁts (data not shown) nor that
these data revealed the presence of a second compartment. Therefore,
in this study, OCA appeared to be more reliable than NCA for both
rFVIIa and pdFVII.
Our pharmacokinetic analyses showed that rFVIIa had shorter
half-lifes and increased volume of distribution as compared to pdFVII.
Both observations may explain the long lasting effect of both products
in factor VII deﬁcient patients who are prophylactically treated with
either 20 μg/kg rFVIIa or 25 IU/ kg pdVII two to three times a week.
Additionally some differences were observed with respect to the
mathematical calculations. OCA resulted in shorter half-lives, higher
clearance levels and higher Vss than NCA.
rFVIIa administration resulted, apart from a shorter half-life, in
higher activity levels as compared to pdFVII, most likely caused by
the fact that rFVIIa is an active enzyme, while pdFVII is a zymogen,
which requires activation before it can exert its function. Moreover
the volume of distribution of rFVIIa was increased when compared
to pdFVII. Volumes of distribution up to 50 ml/kg correspond to the
plasma volume [18] whereas levels up to 200–400 ml/kg also include
extracellular ﬂuids. This increased volume of distribution levels was
only observed when the pharmacokinetic parameters were calculated
on basis of FVIIa activity and not when calculated based on FVII activ-
ity or FVII antigen levels. This observation ﬁts with a murine study,
which assumed that rFVIIa is also localized in the extravascular
space [17] thereby suggesting that the altered distribution of rFVIIa
may explain its prolonged pharmacological effect.
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Fig. 1. Factor VII parameters in FVII deﬁcient patients treatedwith rFVIIa and pdFVII. Median
levels of FVIIa activity (A), FVII levels (B) and FVII antigen levels (C) after administration of
rFVIIa (ﬁlled squares) or pdFVII (open squares). Error bars indicate 25% and 75% Interquartile
ranges.
Table 3
Pharmacokinetics of rFVIIa and pdFVII determined by OCA and NCA. Doses were calculated
FVII = 500 ng/ml FVII and plasma concentration (micrograms/l) time proﬁles were analy
AUC, Cmax, CL, MRT and half-life. IVR was calculated using the observed Cmax values. Re
FVII(a)
compound
PK data
based on
Vss (ml/kg) AUC (μg/l*h) Cmax (μg/l)
25%
perc.
median 75%
perc.
25%
perc.
median 75%
perc.
25%
perc.
median 75%
perc.
rFVIIa FVIIa
activity
OCA 127 175 221 86 180 258 82 128 153
NCA 139 236 385 115 227 293 89 150 172
FVII
activity
OCA 46 64 85 250 330 406 237 338 524
NCA 107 206 380 315 431 604 294 386 687
FVII
antigen
OCA 60 84 94 451 752 887 187 251 307
NCA 66 102 182 974 1414 1641 217 274 395
pdFVII FVIIa
activity
OCA x x x x x x x x x
NCA x x x x x x x x x
FVII
activity
OCA 62 77 122 510 673 745 86 172 207
NCA 79 122 165 734 781 1045 78 218 239
FVII
antigen
OCA 49 63 83 904 1092 1293 198 239 309
NCA 53 62 72 1256 1511 1728 205 268 314
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than for pdFVII since pdFVII is the zymogen of FVIIa. Moreover maxi-
mum FVII activity levels and pharmacokinetic Cmax levels, based on
FVII activity, were quite different for both products; rFVIIa administra-
tion resulted in FVII activity levels that were twice as high than after
administration of pdFVII. The reason for this discrepancy might not
be due to the amount of product injected since the antigen recovery
of 20 μg/kg rFVIIa and 25 IU/kg pdFVIIwere notably similar, indicating
that the dosages were comparable. Furthermore it may not expected
that the existence of a second compartment may explain these results,
since the volumes of distribution calculatedwith FVII activity levels do
not differ. The only alternative explanationmight again be the presen-
tation of the protein; zymogen versus active enzyme. The dosages of
rFVIIa and pdFVII used in this study were reported before in several
case studies, and theoretically should result in levels of 15-20% of fac-
tor VII clotting activity to get a good hemostatic response. In fact, this
study showed higher levels for both FVII activity and FVII antigen
levels.
Clearance of both FVIIa and FVII activity levels was much faster than
clearance of FVII antigen levels. This may be explained by complex
formation of FVIIa with antithrombin and with α2-macroglobulin, as
was shown both in vitro and in vivo (rats), but we did not measure
this ourselves [19–21]. This complex formation could cause
de-activation of FVIIa. However, the FVIIa-antithrombin and
FVIIa-α2-macroglobulin complexes are not faster cleared than FVIIa or
FVII. Since these complexes can also be detected by the FVII antigen
assay, this may explain the prolonged antigen half-lifes [20] for both
products.
Our pharmacokinetic data obtained for pdFVII are comparablewith
previous reports. Mariani et al. [7] reported in seven severe FVII deﬁ-
cient patients half-lifes for pdFVII ranging from 2.7-3.8 hours, which
are in concordance with the results from Dike et al. (n = 6, range
2.5 till 4 hours) [8]. Rivard et al., performed pharmacokinetic studies
in eleven patients and analyzed the results by NCA and OCA [6].
Their estimated half-lifes were considerably higher with mean levels
of 5.3 hours for the NCA and 6.5 hours for the OCA. As individual
half-lifes were reported which did not show a Gaussian distribution,
the half-lifes were recalculated and median levels were 4.8 hours for
NCA and 5.4 hours for OCA based on FVII levels. Despite the fact that
their study observed longer half-lifes for NCA, their results can be con-
sidered within the same range as our results although detailed infor-
mation to determine the volume of distribution is lacking. Berrettini
et al. determined pharmacokinetics after administration of 15 and
30 μg/kg rFVIIa to ﬁve severe FVII deﬁcient patients using NCA,based
on both FVIIa activity and FVII levels, respectively [10]. Based on
FVIIa activity levels the mean half-lifes ranged from 2.49 (15 μg/kg)
to 2.62 hours (30 μg/kg) and where comparable to the mean half-to micrograms using the conversion factors 1 IU/ml FVIIa = 20 ng/ml FVIIa; 1 IU/ml
zed according to OCA and NCA as described in Materials and Methods, providing Vss,
sults are noted as median levels with 25 and 75% interquartile ranges.
IVR ((ug/dl)/ug/kg) CL (ml/(kg*h)) MRT (h) T½ (h)
25%
perc.
median 75%
perc.
25%
perc.
median 75%
perc.
25%
perc.
median 75%
perc.
25%
perc.
median 75%
perc.
0.46 0.70 0.78 81 120 224 1.1 1.3 1.8 0.8 0.9 1.3
77 101 160 1.7 2.1 2.3 1.4 1.6 2.1
1.50 2.05 3.14 40 66 86 0.8 1.0 1.0 0.5 0.7 0.7
28 46 72 3.9 4.5 6.5 1.0 1.4 1.7
1.21 1.39 1.69 22 26 38 1.8 2.8 4.1 1.3 2.1 2.6
12 14 20 5.0 5.7 9.0 4.3 5.1 8.5
x x x x x x x x x x x x
x x x x x x x x x
0.77 1.45 1.78 17 20 27 2.9 4.6 7.8 2.0 3.2 5.4
12 14 18 6.3 7.3 9.0 5.6 6.8 8.3
1.40 2.08 2.28 11 13 18 3.5 4.5 5.2 2.4 3.2 3.7
8 9 13 5.1 5.8 6.5 4.7 5.8 6.2
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Fig. 2. Comparison of pharmacokinetic parameters after rFVIIa and pdFVII administration in factor VII deﬁcient patients. Pharmacokinetic parameters for rFVIIa and pdFVII activity
and antigen determined with OCA (A,C,E,G) or NCA (B,D,F,H). Values for individual patients are displayed and connected.
261N.C.J. Mathijssen et al. / Thrombosis Research 132 (2013) 256–262lifes based on the FVII activity levels of 2.82 hours (15 μg/kg) and
3.11 hours (30 μg/kg), respectively. However, their volumes of distri-
bution at steady state did not differ between the FVIIa-based and
FVII based pharmacokinetic determinations (210–290 ml/kg). In this
study, however, the individual levels were not reported and Gaussian
distribution cannot be ruled out.In conclusion, we determined both rFVIIa- and pdFVII pharmacoki-
netics in nine FVII deﬁcient patients. Recombinant activated factor VII
showed signiﬁcantly shorter half-lifes than plasma-derived factor VII.
Volumes of distribution were signiﬁcantly higher for treatment with
recombinant activated factor VII if compared to plasma-derived factor
VII. The longer half-life for plasma-derived and the increased volume
262 N.C.J. Mathijssen et al. / Thrombosis Research 132 (2013) 256–262of distribution for recombinant activated factor VII may explain the
beneﬁcial effect of prophylactic treatment of both products.
Supplementary data to this article can be found online at http://
dx.doi.org/10.1016/j.thromres.2013.05.027.
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